Allarity adds proteomics and cell line research to its laboratory

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Allarity adds proteomics and cell line research to its laboratory

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

September 28, 2026 8:00 AM EDT

        
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib

- New proteomics and cell line capabilities will broaden Allaritys research capabilities to enable external partnerships

TARPON SPRINGS, Fla., September 28, 2026 Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)a differentiated, dual PARP and WNT pathway inhibitor
today announced that it has expanded the capabilities of its in-house medical laboratory to include proteomics and cell line research.

The new capabilities build on the laboratorys existing transcriptomics... More